<i>CDK12</i> Deficiency and the Immune Microenvironment in Prostate Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33199495.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3877 and PMC identifier 7855343.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4<sup>+</sup>FOXP3<sup>-</sup> T cells were increased compared with CDK12-proficient controls.<i>See related article by Rescigno et al., p. 566</i>.
Medical subject headings
- Cyclin-Dependent Kinases
- Prostatic Neoplasms